Salomé Glauzy1, Marco Boccitto1, Jason M Bannock1, Fabien R Delmotte1, David Saadoun2, Patrice Cacoub2, John A Ice3, Kathy L Sivils4, Judith A James4, Sandra L Wolin1, Eric Meffre1. 1. Yale University School of Medicine, New Haven, Connecticut. 2. Sorbonne Universités, UPMC Université Paris 06, UMR 7211, Inflammation-Immunopathology-Biotherapy Department, INSERM, UMR S 959, CNRS, FRE3632, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, National Reference Center for Autoimmune and Autoinflammatory Diseases, Paris, France. 3. Oklahoma Medical Research Foundation, Oklahoma City. 4. Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.
Abstract
OBJECTIVE: Patients with Sjögren's syndrome (SS) are prone to develop malignant lymphomas, and a correlation has been established between the lymphoproliferations occurring in these disorders and the presence in patients' blood of an unusual B cell population that down-regulates complement receptor 2/CD21. This study was undertaken to identify the B cell compartment from which these lymphoproliferations emerge and determine the mechanisms that promote clonal B cell expansion in patients with SS. METHODS: The reactivity of antibodies expressed by CD19+CD10-CD27-IgM+CD21-/low cells isolated from the blood of patients with SS was tested using a polymerase chain reaction-based approach that allows us to clone and express, in vitro, recombinant antibodies produced by single B cells. RESULTS: Clonal expansions were identified in CD21-/low B cells isolated from the peripheral blood of 3 patients with SS. These lymphoproliferations expressed B cell receptors (BCRs) that displayed somatic hypermutation lineage trees characteristic of a strong selection by antigens; one of these antigens was identified as a ribosomal self antigen. When the mutated BCR sequences expressed by the expanded CD21-/low B cell clones from patients with SS were reverted in vitro to their germline counterparts, one clone remained autoreactive. CONCLUSION: Clonal lymphoproliferations in patients with SS preferentially accumulate in the autoreactive CD21-/low B cell compartment often expanded in these subjects, and recognition of self antigens may drive the clonal B cell expansion while further refining BCR self-reactivity.
OBJECTIVE:Patients with Sjögren's syndrome (SS) are prone to develop malignant lymphomas, and a correlation has been established between the lymphoproliferations occurring in these disorders and the presence in patients' blood of an unusual B cell population that down-regulates complement receptor 2/CD21. This study was undertaken to identify the B cell compartment from which these lymphoproliferations emerge and determine the mechanisms that promote clonal B cell expansion in patients with SS. METHODS: The reactivity of antibodies expressed by CD19+CD10-CD27-IgM+CD21-/low cells isolated from the blood of patients with SS was tested using a polymerase chain reaction-based approach that allows us to clone and express, in vitro, recombinant antibodies produced by single B cells. RESULTS: Clonal expansions were identified in CD21-/low B cells isolated from the peripheral blood of 3 patients with SS. These lymphoproliferations expressed B cell receptors (BCRs) that displayed somatic hypermutation lineage trees characteristic of a strong selection by antigens; one of these antigens was identified as a ribosomal self antigen. When the mutated BCR sequences expressed by the expanded CD21-/low B cell clones from patients with SS were reverted in vitro to their germline counterparts, one clone remained autoreactive. CONCLUSION: Clonal lymphoproliferations in patients with SS preferentially accumulate in the autoreactive CD21-/low B cell compartment often expanded in these subjects, and recognition of self antigens may drive the clonal B cell expansion while further refining BCR self-reactivity.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin Journal: Blood Date: 2011-03-18 Impact factor: 22.113
Authors: Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi Journal: Blood Date: 2010-01-28 Impact factor: 22.113
Authors: Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel Journal: J Exp Med Date: 2005-04-18 Impact factor: 14.307
Authors: Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein Journal: J Exp Med Date: 2005-10-31 Impact factor: 14.307
Authors: Ignacio Sanz; Chungwen Wei; Scott A Jenks; Kevin S Cashman; Christopher Tipton; Matthew C Woodruff; Jennifer Hom; F Eun-Hyung Lee Journal: Front Immunol Date: 2019-10-18 Impact factor: 7.561
Authors: Jennifer Young-Glazer; Alberto Cisneros; Erin M Wilfong; Scott A Smith; Leslie J Crofford; Rachel H Bonami Journal: Arthritis Res Ther Date: 2021-01-19 Impact factor: 5.606
Authors: Hector Rincon-Arevalo; Annika Wiedemann; Ana-Luisa Stefanski; Marie Lettau; Franziska Szelinski; Sebastian Fuchs; Andreas Philipp Frei; Malte Steinberg; Tony Kam-Thong; Klas Hatje; Baerbel Keller; Klaus Warnatz; Andreas Radbruch; Andreia C Lino; Eva Schrezenmeier; Thomas Dörner Journal: Front Immunol Date: 2021-03-12 Impact factor: 7.561
Authors: Bryan A Joosse; James H Jackson; Alberto Cisneros; Austin B Santhin; Scott A Smith; Daniel J Moore; Leslie J Crofford; Erin M Wilfong; Rachel H Bonami Journal: Front Immunol Date: 2021-05-24 Impact factor: 8.786